S. Conrad et al., GYRA MUTATIONS IN HIGH-LEVEL FLUOROQUINOLONE-RESISTANT CLINICAL ISOLATES OF ESCHERICHIA-COLI, Journal of antimicrobial chemotherapy, 38(3), 1996, pp. 443-455
Double mutations in the quinolone resistance determining region of the
gyrase A gene (gyrA) have recently been reported to be associated wit
h high-level resistance to fluoroquinolones in clinical isolates of Es
cherichia coli. We examined the type and frequency of such mutations i
n a large number of clinical isolates that were obtained from ten diff
erent geographical locations and had been genotypically characterized
by pulsed field gel electrophoresis (PFGE) of chromosomal DNA digests.
Of 36 isolates with ofloxacin MICs greater than or equal to 4 mg/L th
at represented at least 24 distinct genotypes, 35 had double mutations
at amino acid codons 83 and 87 of gyrA, while two isolates with oflox
acin MICs of 0.5 and 4 mg/L, respectively, each had a single mutation
at codon 83. Mutations at codon Ser-83 were uniform, resulting in subs
titution by Leu. The additional mutations at amino acid codon 87 in th
e 35 double-mutants were diverse, resulting in Asp-87 substitutions by
residues Asn (23 isolates), Gly (7 isolates), Tyr (4 isolates), or Hi
s (1 isolate) without a discernable correlation with fluoroquinolone M
ICs or with phenotypic resistance to chemically unrelated antibacteria
l agents. Maximal differences between MICs of double-mutants with the
same amino acid substitution were eight-fold. The changes of amino aci
d residues at codon Asp-87 differed between individual patient isolate
s with the same genotype (and similar MICs), suggesting that the amino
acid codon 87 mutations (and possibly the development of high-level f
luoroquinolone resistance) might have occurred after the transmission
and sharing of a precursor strain carrying the Ser-83-->Leu mutation.